# Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer

> **NCT00281021** · PHASE2 · TERMINATED · sponsor: **University of Louisville** · enrollment: 26 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung

## Interventions

- **DRUG:** Erlotinib plus Digoxin

## Key facts

- **NCT ID:** NCT00281021
- **Lead sponsor:** University of Louisville
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2006-02
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 26 (ACTUAL)
- **Why stopped:** Interim analysis revealed that only 1 patient had a partial response.
- **Last updated:** 2018-03-29

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00281021

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00281021, "Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-09-10 from https://api.ai-analytics.org/clinical/NCT00281021. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*